ACELYRIN Inc (SLRN) News & EventsSLRNNews & EventsACELYRIN Inc

Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN (SLRN) reiterated its confidence that the proposed combination with Alumis (ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee, said, "The ACELYRIN Board and management team are confident that the proposed merger with Alumis represents the most value-maximizing path forward for our company's stockholders. The agreement with Alumis follows a comprehensive and competitive process facilitated by the ACELYRIN Board. Furthermore, it reflects successful efforts by our Board to negotiate a revised agreement with a meaningful increase in ACELYRIN stockholders' ownership in the combined company. With the Special Meeting just weeks away, we urge ACELYRIN stockholders to vote FOR the proposed merger with Alumis to protect the value of your investment." The ACELYRIN Board's disinterested and independent directors unanimously recommend that stockholders vote "FOR" the merger with Alumis. .

Alumis and Acelyrin sign ammended merger agreement

Alumis (ALMS) and Acelyrin (SLRN) announced an amendment to the existing terms of their previously announced merger agreement: Acelyrin stockholders will now receive 0.4814 shares of Alumis common stock for each share of Acelyrin common stock owned, representing an increase in the ownership percentage of the combined company over the original definitive merger agreement. With the amended exchange ratio, Alumis stockholders will own approximately 52% of the combined company and Acelyrin stockholders will own approximately 48% on a fully diluted basis. With a pro forma cash position of approximately $737M as of December 31, 2024, and continued operating discipline, Alumis expects runway to advance the combined company's pipeline through multiple planned key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027. The amended merger agreement was unanimously recommended and approved by the disinterested directors of each company's Board. Stockholders representing approximately 62% of Alumis voting common stock and approximately 24% of Acelyrin common stock have entered into voting agreements in support of the transaction. The companies continue to expect to close the transaction during Q2, subject to the approval by both companies' stockholders and satisfaction of other customary closing conditions.